At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 37 enrolled
Drug / intervention
Botulinum toxin type Adrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Novel Concepts for OnabotulinumtoxinA (Botox) Mechanisms of Action: Role in Altering the Molecular Environment in Which Pain Fibers Exist
In Brief
A Phase 4 clinical trial evaluating Botulinum toxin type A for Migraine. Completed, enrolled 37 participants across 1 site.
Detailed Summary
To compare Botox-treated and Botox-untreated symptomatic tissues (defined as areas where the head hurts and the pain is felt) of chronic migraine (CM) patients using molecular studies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesUnited States
CollaboratorsBeth Israel Deaconess Medical Center
Timeline
Phase 4CompletedFinished
201820192020202120222023202420252026
Enrollment StartDec 2017
First PostedDec 2017
Primary CompletionAug 2023
Study CompletionDec 2023
TodayJul 2026
First PostedDec 21, 2017
Enrollment StartDec 1, 2017
Primary CompletionAug 1, 2023
Study CompletionDec 1, 2023
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 8.5 years ago
Interventions
Botulinum toxin type Adrug
Injection of Botulinum toxin type A in back of head